Related Experiment Video
Updated: May 12, 2026
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
MIBG molecular imaging for evaluating response to chemotherapy in patients with malignant pheochromocytoma:
Simone Maurea1, Giovanni Fiumara, Teresa Pellegrino
1Department of Advanced Biomedical Sciences, University Federico II, Napoli, Italy.
Abstract:
Malignant pheochromocytomas respond to chemotherapy with a reduction in tumor size and catecholamine secretion. We investigated the usefulness of molecular imaging with meta-iodobenzylguanidine (MIBG) for evaluating the effects of chemotherapy in patients with malignant pheochromocytoma. Six patients were studied before and after 6 ± 4 months of combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine. Urinary catecholamines, metanephrines, and vanillylmandelic acid (VMA) levels were measured before and after chemotherapy. [(131)I]MIBG uptake was calculated for each tumor lesion on images before and after chemotherapy. An intensity ratio (IR) of abnormal to normal tissue count density was used to evaluate the change in lesion activity with therapy. Urinary catecholamines, metanephrines, and VMA significantly decreased with chemotherapy. MIBG uptake decreased in most lesions and the reduction in overall IR correlated with the reduction in urinary VMA. However, the change in individual lesions was variable and MIBG IR did not change or increased in a number of lesions. In conclusion, MIBG imaging is useful in the evaluation of patients with malignant pheochromocytoma who are receiving chemotherapy. It can provide not only a measure of overall effectiveness of treatment but also allows a lesion-by-lesion evaluation of the heterogeneity of response to chemotherapy.
Insights
Meta-iodobenzylguanidine (MIBG) imaging helps evaluate chemotherapy effectiveness in malignant pheochromocytoma. This molecular imaging approach tracks changes in tumor lesions and catecholamine levels, aiding treatment assessment.
Area of Science:
- Oncology
- Nuclear Medicine
- Endocrinology
Background:
- Malignant pheochromocytomas are rare tumors that can be treated with chemotherapy.
- Evaluating treatment response in these tumors is crucial for patient management.
Purpose of the Study:
- To assess the utility of meta-iodobenzylguanidine (MIBG) molecular imaging in evaluating chemotherapy effects on malignant pheochromocytoma.
- To correlate MIBG imaging findings with biochemical markers of tumor activity.
Main Methods:
- Six patients with malignant pheochromocytoma underwent combination chemotherapy (cyclophosphamide, vincristine, dacarbazine).
- [(131)I]MIBG uptake and intensity ratio (IR) were measured before and after therapy.
- Urinary catecholamines, metanephrines, and vanillylmandelic acid (VMA) were analyzed pre- and post-chemotherapy.
Main Results:
- Chemotherapy led to significant reductions in urinary catecholamines, metanephrines, and VMA.
- MIBG uptake generally decreased in tumor lesions, with reduced IR correlating with VMA reduction.
- Individual lesion responses varied, with some showing no change or increased MIBG IR.
Conclusions:
- MIBG imaging is a valuable tool for assessing chemotherapy effectiveness in malignant pheochromocytoma.
- It provides both overall treatment efficacy and lesion-specific response heterogeneity.
- MIBG imaging complements biochemical markers in monitoring treatment outcomes.
